Fol. Biol. 2022, 68, 153-157
https://doi.org/10.14712/fb2022068040153
Circulating Cell-Free DNA Extraction from Liquid Biopsy for Cancer Research
References
1. 2019) Measuring tumor mutation burden in cell-free DNA: advantages and limits. Transl. Lung Cancer Res. 8, 553-555.
< , A., Weiss, G. J. (https://doi.org/10.21037/tlcr.2019.03.04>
2. 2017) Cell-free DNA in non-small cell lung cancer. Acta Med. Litu. 24, 138-144.
, V., Schveigert, D., Cicėnas, S. (
3. 2019) Liquid biopsy: a new avenue in pathology. Cytopathology 30, 138-143.
< , R. K., Pandey, T., Dey, P. (https://doi.org/10.1111/cyt.12661>
4. 2018) Liquid biopsy and its role in an advanced clinical trial for lung cancer. Exp. Biol. Med. 243, 262-271.
< , D. J. Jr., Steliga, M., Shin, I. J., Yoon, D., Arnaoutakis, K., Hutchins, L., Liu, M., Liem, J., Walker, K., Pereira, A., Yang, M. (https://doi.org/10.1177/1535370217750087>
5. 2020) Liquid biopsy-based biomarkers of treatment response and resistance. Cancer Cell 37, 485-495.
< , E., Rothwell, D. G., Brady, G., Dive, C. (https://doi.org/10.1016/j.ccell.2020.03.012>
6. 2019) Life and death of circulating cell-free DNA. Cancer Biol. Ther. 20, 1057-1067.
< , A., Schwartz, R., Peretz, T., Grinshpun, A. (https://doi.org/10.1080/15384047.2019.1598759>
7. 2020) Plasma vs. serum in circulating tumor DNA measurement: characterization by DNA fragment sizing and digital droplet polymerase chain reaction. Clin. Chem. Lab. Med. 58, 527-532.
< , J., Kim, M., Seong, M., Kim, H., Lee, Y., Kang, H. (https://doi.org/10.1515/cclm-2019-0896>
8. 2021) Liquid biopsy: a family of possible diagnostic tools. Diagnostics (Basel) 11, 1391.
< , B. (https://doi.org/10.3390/diagnostics11081391>
9. 2017) Guide to detecting epidermal growth factor receptor (EGFR) mutations in ctDNA of patients with advanced non-small-cell lung cancer. Oncotarget 8, 12501-12516.
< , N., Denis, M. G., Thress, K. S., Ratcliffe, M., Reck, M. (https://doi.org/10.18632/oncotarget.13915>
10. 2020) ctDNA as a cancer biomarker: a broad overview. Crit. Rev. Oncol. Hematol. 155, 103109.
< , L. S., Heringer M., Ferrer, V. P. (https://doi.org/10.1016/j.critrevonc.2020.103109>
11. 2020) Plasma or serum: which is preferable for mutation detection in liquid biopsy? Clin. Chem. 66, 946-957.
< , F., Chin, Y. M., Chan, H. T., Nagayama, S., Miyauchi, E., Low, S. K., Nakamura, Y. (https://doi.org/10.1093/clinchem/hvaa103>
12. 2004) Quantification of circulating DNA in the plasma and serum of cancer patients. Ann. N. Y. Acad. Sci. 1022, 17-24.
< , B., O’Day, S. J., Hoon, D. S. (https://doi.org/10.1196/annals.1318.004>
13. 2006) Higher amount of free circulating DNA in serum than in plasma is not mainly caused by contaminated extraneous DNA during separation. Ann. N. Y. Acad. Sci. 1075, 299-307.
< , N., Hiramatsu, S., Hoon, D. S. (https://doi.org/10.1196/annals.1368.040>
14. 2018) Potential of circulating biomarkers in liquid biopsy diagnostics. Biotechniques 65, 187-189.
< , J. C., Lim, C. T. (https://doi.org/10.2144/btn-2018-0093>